Given the labyrinth of patent litigation ongoing between companies that were working on mRNA vaccines during the pandemic, a merger agreement between two of them – BioNTech and CureVac – raised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback